Mounjaro is not FDA approved for weight loss. It is approved only for improving blood sugar control in adults and children 10 and older with type 2 diabetes. However, the exact same drug, tirzepatide, is sold under a different brand name, Zepbound, which is FDA approved for chronic weight management. Both products are made by Eli Lilly and are molecularly identical.
Why Two Brand Names for the Same Drug
Eli Lilly intentionally created two separate brands for tirzepatide. Mounjaro launched first as a diabetes treatment, and Zepbound followed with its own FDA approval specifically for weight loss and obstructive sleep apnea. The dual branding allows for different insurance coverage pathways, different prescribing guidelines, and compliance with FDA labeling rules that require separate approvals for separate medical conditions.
This distinction matters most when it comes to insurance. A plan that covers Mounjaro for diabetes may not cover it for weight loss, and vice versa. Zepbound is more likely to be covered (or at least considered) by insurers when the prescription is written for weight management.
Off-Label Prescribing for Weight Loss
Despite lacking an official weight loss indication, Mounjaro is frequently prescribed off-label for weight management. Doctors can legally prescribe any FDA-approved medication for uses beyond its labeled indication if they believe the benefit is justified. For weight loss specifically, doctors typically consider Mounjaro when a patient has a BMI of 30 or higher, or a BMI of 27 or higher combined with a weight-related condition like high blood pressure, high cholesterol, or sleep apnea.
The catch with off-label use is that your insurance company is far less likely to cover the cost. You may need prior authorization, an appeal, or you may end up paying out of pocket. If your primary goal is weight loss rather than blood sugar control, asking your doctor about Zepbound directly may simplify the insurance process.
How Tirzepatide Works
Tirzepatide targets two hormone systems at once, which sets it apart from older weight loss medications that only target one. It activates both the GIP receptor and the GLP-1 receptor, two pathways involved in appetite regulation, blood sugar control, and how your body processes food. Most competing medications, like semaglutide (Wegovy, Ozempic), only activate the GLP-1 pathway.
The GIP receptor activity appears to improve insulin sensitivity through a mechanism that works independently of weight loss itself. Meanwhile, the GLP-1 activity slows stomach emptying, reduces appetite, and helps regulate blood sugar after meals. The combination of both pathways is thought to explain why tirzepatide produces larger weight reductions than GLP-1-only drugs in head-to-head comparisons.
Weight Loss Results From Clinical Trials
The SURMOUNT-1 trial, the landmark study that led to Zepbound’s approval, tested tirzepatide in people with obesity or overweight (without diabetes) over 72 weeks. The results were striking. Participants on the lowest dose (5 mg) lost an average of 15% of their body weight. Those on 10 mg lost 19.5%, and those on the highest dose (15 mg) lost 20.9%. All three doses significantly outperformed placebo.
To put that in perspective, a person weighing 250 pounds on the highest dose would lose roughly 52 pounds over about a year and a half. These are averages, meaning some people lost more and some lost less, but the consistency across dose levels was notable. The weight loss was achieved alongside diet and exercise, which were part of the trial protocol for all groups including placebo.
Dosing and What to Expect
Tirzepatide starts at 2.5 mg per week, which is considered a titration dose rather than a therapeutic one. The purpose of starting low is to let your body adjust and reduce the severity of side effects. Every four weeks, your dose increases by 2.5 mg until you and your doctor find the right balance of effectiveness and tolerability, up to a maximum of 15 mg per week.
The medication comes as a once-weekly injection using a prefilled autoinjector pen, stored in the refrigerator. The injection is subcutaneous, meaning it goes just under the skin, typically in the abdomen, thigh, or upper arm. Most people rotate injection sites each week to avoid irritation.
Common Side Effects
Gastrointestinal symptoms are by far the most common side effects, and they tend to be worst during the early weeks and after each dose increase. In clinical data, nausea affected 30 to 40% of users, diarrhea occurred in 20 to 25%, vomiting in 15 to 18%, and constipation in 12 to 15%. For most people, these symptoms are mild to moderate and fade as the body adjusts to each new dose level.
Eating smaller meals, avoiding high-fat foods, and staying hydrated can help manage the digestive side effects during titration. If symptoms are severe or persistent at a given dose, doctors will sometimes hold at that dose for an extra four weeks before increasing again.
Safety Warnings
Tirzepatide carries a boxed warning, the most serious type of FDA safety alert, regarding thyroid tumors. In rat studies, the drug caused thyroid C-cell tumors at doses comparable to those used in humans. Whether this translates to a risk in people is still unknown, but as a precaution, tirzepatide is contraindicated for anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. Symptoms to be aware of include a lump in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness.
The medication is also contraindicated for anyone with a known serious allergy to tirzepatide. Rare cases of severe allergic reactions, including anaphylaxis, have been reported.
Mounjaro vs. Zepbound: Which to Ask About
If you have type 2 diabetes and also want to lose weight, Mounjaro covers both goals with a single prescription and is more likely to be covered by insurance for the diabetes indication. If you don’t have diabetes and your primary concern is weight management, Zepbound is the version with the matching FDA approval, which generally makes the insurance and prescribing process more straightforward.
The medication inside the pen is identical either way. The difference is entirely about labeling, insurance billing codes, and what your doctor writes on the prescription. Your doctor can help determine which brand name gives you the best path to coverage based on your specific diagnoses and insurance plan.